Dr. Adamson serves as chair of the international consortium Children's Oncology Group and on the National Cancer Advisory Board. In addition to his national and international leadership roles in pediatric oncology, Dr. Adamson maintains a dynamic research program on pediatric clinical-translational drug development, with a strong focus on childhood cancer drug development.
Dr. Jawad has more than 20 years’ experience in designing, analyzing, and reporting medical research studies and clinical trials. He served as a co-investigator in numerous research studies covering a variety of child illnesses such as diabetes, sickle cell, immunology, infections, and mental illnesses.
Dr. Zorc's work focuses on the intersection of interventional clinical research, quality improvement (QI), and clinical informatics. He has formal certification in epidemiology, QI methodology, and clinical informatics, and has participated in multi-center research networks, guideline and improvement collaboratives, and electronic health record development locally and nationally.
Dr. Balis's research focuses on the clinical pharmacology of anticancer drugs, new drug development, and clinical trial design and endpoints. He studies the pharmacokinetics and pharmacodynamics of anticancer drugs and has applied pharmacological principles to clinical trial design and clinical drug development. He is developing new biomarkers to serve as surrogate endpoints of drug toxicity or efficacy in clinical trials.
Dr. Li's methodology research interests include survival analysis, longitudinal data analysis, Bayesian methods, and clinical trial design. Her current research involves statistical designs and analysis for early phase cancer clinical trials and cancer trials with multiple survival endpoints.
Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.
Dr. Eichenwald's research interests include clinical trials and quality improvement in neonatal-perinatal medicine. He has extensive experience in the conduct of multicenter clinical trials, having served as a site principal investigator for several funded, multicenter randomized trials of interventions aimed at improving outcomes of premature newborns.
Dr. Levine has an active laboratory research program that complements and extends his clinical studies. He has identified the molecular basis of several inherited disorders of mineral metabolism. His research interests extend to the molecular basis for embryological development of the parathyroid glands.
Dr. Olson aims to improve diagnostics and treatment of bone marrow failure (BMF) syndromes, and to improve clinical hematopoietic stem cell transplantation (HSCT) outcomes. He conducts clinical trials of HSCT for non-malignant hematologic diseases. His laboratory explores both basic and translational research focused on genomics of BMF and the impact of BMF on hematopoietic niche function during HSCT.
Dr. Pamela Weiss is an experienced academic pediatric rheumatologist with advanced training in clinical epidemiology and a focus on early diagnosis, accurate phenotyping, and targeted treatment of children with juvenile arthritis. Her research consists of a mixture of prospective interventional, prospective observational and retrospective large database-driven work.